Half-year report · Q2

Period2025-01-01 → 2025-06-30
Filed2025-08-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales (5-year summary)
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet income loss (5-year summary)
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Total assets¥2.0bnat 2025-06-30StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.6bnat 2024-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥443mat 2025-06-30StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2025-06-30StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 427
ItemContextValueUnit
Next fiscal year start dateFilingDateInstant-
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant-
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant-
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of reporting company (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所(グロース市場)
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数は100株であります。
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)小川 恭弘
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)兵庫県加古川市
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)楽天証券株式会社
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)東京都港区南青山2丁目6番21号
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)渡邊 賢二
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)北海道札幌市中央区
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)太田 邦史
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)東京都板橋区
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)江平 文茂
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)東京都荒川区
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)御所野 侃
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)埼玉県越谷市
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)巻幡 俊
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)広島県尾道市
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)飯作 哲男
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)東京都江東区
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)山戸 福太郎
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)大阪府大阪市中央区
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)平田 重一
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)愛媛県松山市
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsOtherMember
Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。単元株式数 100株
Description issued shares voting rightsCurrentQuarterInstant_SharesLessThanOneUnitMember-
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)株式会社カイオム・バイオサイエンス

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-06-30pass